LOS ANGELES, CA--(Marketwired - Jul 13, 2015) - Marathon Patent Group, Inc. (
The '260 patent had previously been accused of invalidity by Stryker GmbH & Co. KG ("Stryker"), Docket No. 4 Ni 4/14 (EP). In a nullity hearing held June 19, 2015, the five-judge panel at the Federal Patent Court, after carefully considering all facts and arguments brought by Stryker, deliberated and returned with the unrestricted verdict that "All claims are valid." The Federal Patent Court's decision is subject to potential appeal.
The Court subsequently dismissed the infringement action for lack of sufficient evidence to prove the chain of title. The Company is securing the necessary documents to substantiate the chain of title and upon successful completion, will use all legal means available to enforce its valid patents.
On July 21, 2015, the Federal Patent Court will hear oral arguments on the validity of EP 1 938 765 B1 (the '765 patent).
On October 29, 2015, the Higher Regional Court of Düsseldorf will hold an Oral Hearing regarding Stryker's appeal of the infringement rulings against it for both the '260 and '765 patents.
On December 12, 2015, the Higher Regional Court of Munich will hold an Oral Hearing regarding Ulrich's appeal of the ruling rejecting Ulrich's request that MedTech Development Deutschland GmbH should pay a bond prior to litigating the '260 patent before the Munich Court.
At the hearing for the Italian lawsuit commenced by Pan Medical Ltd. against Orthophoenix and MedTech the parties discussed the connection between the Italian proceedings and the German lawsuit as well as the legal status of the patents involved, EP1104260 and EP 1938765. In particular, Pan Medical joined the claim proposed by Orthophoenix and MedTech of discontinuance of the matter in issue with reference to patent EP1104260. The judge authorized the submission of three subsequent defensive briefs to allow the parties to specify their claims, file pertinent documentation and indicate the evidence relevant to their case. The next hearing before the Italian judge is scheduled for November 4, 2015.
About Marathon Patent Group
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon's strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.
About Noerr LLP, attorney-of-record of MedTech Development Deutschland GmbH
Noerr is one of the top European law firms with more than 500 professionals in Germany, Europe and the USA. The firm delivers real value to clients by devising and handling the right solutions to complex and sophisticated legal matters. The Noerr difference is its unique combination of legal excellence, creative thinking, international experience and in-depth industry knowledge.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.